[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Foodborne Diseases Treatment Market, 2012-2023

January 2018 | 207 pages | ID: F9B2BC4EAEDEN
Precision Business Insights (PBI)

US$ 4,400.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Global Foodborne diseases cover a broad spectrum of illnesses that are affecting the people worldwide. These diseases are due to the intake of food contaminated with harmful microorganisms or chemicals. The contamination occurs from any way either soil, water or air. The most common foodborne infections are caused by three bacteria campylobacter, salmonella, and E.coli and by a group of viruses called calicivirus. Clinical symptoms of foodborne diseases seen in gastro intestinal tract. Symptoms include vomiting, diarrhea, and abdominal pain. In some cases, such diseases can also have neurological, gynecological, immunological and other symptoms. Common foodborne diseases include botulism, salmonellosis, traveler’s diarrhoea, gastroenteritis, tapeworm infection and hepatitis A, among others. Global foodborne diseases treatment market is driven by the increasing incidence of foodborne diseases worldwide.

Global Foodborne Diseases Treatment Market

Increase in R&D investment, growing awareness about foodborne disease symptoms due to initiatives of government and non-government organizations such as WHO, and lack of hygiene conditions are boosting the foodborne diseases treatment market worldwide. However, the high cost of R&D investment for development of anti microbial and stringent, time-consuming regulatory procedures are expected to hinder the foodborne diseases market.

Foodborne diseases treatment market has been segmented based on disease, drug class, and distribution channel

Based on drug class, foodborne diseases treatment market is segmented into
  • Antibiotics
  • Anti Diarrhea
  • Fluids and Electrolyte Replenishers
  • Vaccines
  • Others
Based on disease, foodborne diseases treatment is segmented into
  • Botulism
  • Traveler’s Diarrhea
  • Gastroenteritis
  • Toxoplasmosis
  • Others
Based on route of administration, foodborne diseases treatment market is segmented into
  • Parenteral
  • Oral
  • Others
Based on distribution channel, foodborne diseases treatment market is segmented into
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores
Foodborne diseases treatment market is expected to grow at significant CAGR during the forecast period. According to the findings of WHO – “Estimates of the global burden of foodborne diseases” 2015, almost 1 in every10 people fall ill yearly due to contaminated food consumption and 420,000 deaths occour as a result. Market players are adopting drug developments and collaborations as key market strategies.

Geographically Foodborne Diseases Treatment Market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America foodborne diseases treatment market is expected to grow at notable rates due to increase in the prevalence of foodborne diseases such as botulism and toxoplasmosis, and increase in R&D investment by companies on antibiotics and vaccines. Asia Pacific and Africa regions are projecting lucrative opportunity for foodborne diseases treatment market owing to increase in the incidence of foodborne diseases in these regions. According to WHO estimates 2015, Africa and South East Asia regions have the highest incidence and death rates, including children under the age of 5 years. Europe is expected to show significant growth rate owing to increase in R&D investment and healthcare spending.

Some of the market players in foodborne diseases treatment market are Bayer AG (Germany), Johnson & Johnson Services Inc., (U.S.), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K), Novartis AG (Switzerland), XOMA Corporation (U.S.), AlphaVax, Inc. (U.S.), Molecular Targeting Technologies, Inc. (U.S.), and Morphotek Inc. (U.S.) to name a few

In 2015, January, Valneva SE, entered a purchase and sale with Crucell Holland B.V. in order to acquire Crucell Sweden AB and privileges and licenses of dukoral vaccine to treat cholera and traveler’s diarrhea
1. EXECUTIVE SUMMARY

2. GLOBAL FOODBORNE DISEASE TREATMENT MARKET INTRODUCTION

2.1. Global Foodborne Disease Treatment Market – Taxonomy
2.2. Global Foodborne Disease Treatment Market –Definitions
  2.2.1. Drug Class
  2.2.2. Disease
  2.2.3. Route of Administration
  2.2.4. Distribution Channel

3. GLOBAL FOODBORNE DISEASE TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Foodborne Disease Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Foodborne Disease Treatment Market – Regulations
  3.6.1. U.S.
  3.6.2. Europe
  3.6.3. Japan
3.7. Global Foodborne Disease Treatment Market – Drug Class Pipeline Analysis

4. GLOBAL FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL FOODBORNE DISEASE TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Antibiotics
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Anti Diarrhea
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Fluids and Electrolyte Replenishers
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Vaccines
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Others
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis

6. GLOBAL FOODBORNE DISEASE TREATMENT MARKET FORECAST, BY DISEASE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Botulism
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Traveler’s Diarrhea
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Gastroenteritis
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis
6.4. Toxoplasmosis
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.4.3. Market Opportunity Analysis
6.5. Others
  6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.5.3. Market Opportunity Analysis

7. GLOBAL FOODBORNE DISEASE TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Oral
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Parenteral
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Others
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL FOODBORNE DISEASE TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Hospital Pharmacies
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Drug Stores
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis

9. GLOBAL FOODBORNE DISEASE TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.1.3. Market Opportunity Analysis
9.2. Europe
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.3.3. Market Opportunity Analysis
9.4. Latin America
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
  9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.5.3. Market Opportunity Analysis
9.6. Global Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023

10. NORTH AMERICA FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Antibiotics
  10.1.2. Anti Diarrhea
  10.1.3. Fluids and Electrolyte Replenishers
  10.1.4. Vaccines
  10.1.5. Others
10.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.2.1. Botulism
  10.2.2. Traveler’s Diarrhea
  10.2.3. Gastroenteritis
  10.2.4. Toxoplasmosis
  10.2.5. Others
10.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.3.1. Oral
  10.3.2. Parenteral
  10.3.3. Others
10.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.4.1. Hospital Pharmacies
  10.4.2. Retail Pharmacies
  10.4.3. Online Pharmacies
  10.4.4. Drug Stores
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  10.5.1. U.S.
  10.5.2. Canada
10.6. North America Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
10.7. North America Foodborne Disease Treatment Market Dynamics – Trends

11. EUROPE FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Antibiotics
  11.1.2. Anti Diarrhea
  11.1.3. Fluids and Electrolyte Replenishers
  11.1.4. Vaccines
  11.1.5. Others
11.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.2.1. Botulism
  11.2.2. Traveler’s Diarrhea
  11.2.3. Gastroenteritis
  11.2.4. Toxoplasmosis
  11.2.5. Others
11.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Oral
  11.3.2. Parenteral
  11.3.3. Others
11.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.4.1. Hospital Pharmacies
  11.4.2. Retail Pharmacies
  11.4.3. Online Pharmacies
  11.4.4. Drug Stores
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.5.1. Germany
  11.5.2. UK
  11.5.3. France
  11.5.4. Spain
  11.5.5. Italy
  11.5.6. Russia
  11.5.7. Poland
  11.5.8. Rest of Europe
11.6. Europe Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
11.7. Europe Foodborne Disease Treatment Market Dynamics – Trends

12. ASIA-PACIFIC FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Antibiotics
  12.1.2. Anti Diarrhea
  12.1.3. Fluids and Electrolyte Replenishers
  12.1.4. Vaccines
  12.1.5. Others
12.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.2.1. Botulism
  12.2.2. Traveler’s Diarrhea
  12.2.3. Gastroenteritis
  12.2.4. Toxoplasmosis
  12.2.5. Others
12.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.3.1. Oral
  12.3.2. Parenteral
  12.3.3. Others
12.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.4.1. Hospital Pharmacies
  12.4.2. Retail Pharmacies
  12.4.3. Online Pharmacies
  12.4.4. Drug Stores
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
  12.5.1. Japan
  12.5.2. China
  12.5.3. India
  12.5.4. ASEAN
  12.5.5. Australia & New Zealand
  12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
12.7. Asia-Pacific Foodborne Disease Treatment Market Dynamics – Trends

13. LATIN AMERICA FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Antibiotics
  13.1.2. Anti Diarrhea
  13.1.3. Fluids and Electrolyte Replenishers
  13.1.4. Vaccines
  13.1.5. Others
13.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.2.1. Botulism
  13.2.2. Traveler’s Diarrhea
  13.2.3. Gastroenteritis
  13.2.4. Toxoplasmosis
  13.2.5. Others
13.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.3.1. Oral
  13.3.2. Parenteral
  13.3.3. Others
13.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.4.1. Hospital Pharmacies
  13.4.2. Retail Pharmacies
  13.4.3. Online Pharmacies
  13.4.4. Drug Stores
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.5.1. Brazil
  13.5.2. Mexico
  13.5.3. Argentina
  13.5.4. Venezuela
  13.5.5. Rest of Latin America
13.6. Latin America Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
13.7. Latin America Foodborne Disease Treatment Market Dynamics – Trends

14. MIDDLE EAST AND AFRICA FOODBORNE DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

14.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  14.1.1. Antibiotics
  14.1.2. Anti Diarrhea
  14.1.3. Fluids and Electrolyte Replenishers
  14.1.4. Vaccines
  14.1.5. Others
14.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.2.1. Botulism
  14.2.2. Traveler’s Diarrhea
  14.2.3. Gastroenteritis
  14.2.4. Toxoplasmosis
  14.2.5. Others
14.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.3.1. Oral
  14.3.2. Parenteral
  14.3.3. Others
14.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.4.1. Hospital Pharmacies
  14.4.2. Retail Pharmacies
  14.4.3. Online Pharmacies
  14.4.4. Drug Stores
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  14.5.1. Gulf Cooperation Council (GCC) Countries
  14.5.2. Israel
  14.5.3. South Africa
  14.5.4. Rest of MEA
14.6. MEA Foodborne Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Disease, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
14.7. MEA Foodborne Disease Treatment Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  15.2.1. GE Healthcare (U.S.)
  15.2.2. Hitachi, Ltd. (Hitachi Medical Corporation) (Japan)
  15.2.3. Hologic, Inc. (U.S.)
  15.2.4. Koninklijke Philips N.V. (Philips Healthcare) (Netherlands)
  15.2.5. Siemens AG (Germany)
  15.2.6. Carestream Health (U.S.)
  15.2.7. Toshiba Corporation (Japan)
  15.2.8. Shimadzu Corporation (Japan)
  15.2.9. Fujifilm Holdings Corporation (Japan)
  15.2.10. Esaote SpA (Italy)

16. RESEARCH METHODOLOGY

Key Assumptions and Acronyms


More Publications